State Of Sickle Cell Disease 2016 Report: “This Status Quo Is Unacceptable”
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
“Not only are individuals with SCD burdened by the pain and disability that comes with a chronic condition, but they also have very few accessible treatment options due to our fragmented health care system,” said ASH President Charles S. Abrams, MD, of the University of Pennsylvania. “This status quo is unacceptable, and we are setting out to change it. ASH is proud to make a difference for people battling this disease worldwide by teaming up with partners from around the globe to launch the Sickle Cell Disease Coalition.”
ASH will host a press conference today in Washington, D.C., to discuss the findings of the report and issue the Coalition’s global call to action on SCD. These efforts are supported by leading patient advocacy groups, people with SCD and their families, researchers, clinicians, policymakers, industry stakeholders, and foundations. Together, these groups are pledging their collective efforts to improve care, early diagnosis, treatment, and research.
ASH and its partners have identified several ways to help address the priority areas in the report. These include:
- Access to care: Developing evidence-based guidelines and coordinated health care delivery models to ensure that individuals with SCD can access quality care regardless of age, location, and socioeconomic status.
- Training and Education: Increasing the number of providers who are able to care for those with SCD by educating established clinicians to treat symptoms and complications while encouraging medical trainees to pursue careers in SCD care.
- Research and clinical trials: Investing in strategies to expand use of existing treatments, developing novel therapies, and strengthening curative options while accelerating their discovery.
- Global issues: Expanding newborn screening and early intervention programs, increasing SCD awareness and education, and improving access to quality care in developing regions.
In addition to these priorities, ASH has not only committed to developing and implementing up-to-date guidelines describing the management of acute and chronic complications of SCD, but to also educate health care providers in all settings to recognize and properly respond to SCD symptoms in their everyday practices. Targeted professionals include hematologists, primary care providers, and hospitalists. The Society is also working closely with The Emergency Department Sickle Cell Care Coalition to support their efforts to improve emergency care of individuals with SCD.
ASH is also exploring the development of a consortium of African countries to institute a population-based registry study for newborn screening and early intervention. In addition, the Society will continue to encourage SCD research through advocacy and has developedresearch priorities in SCD and sickle cell trait to encourage the study of unaddressed questions that could make a huge impact on the field. ASH continues to work with Congress and federal agencies to enhance and expand federal sickle cell disease programs.
“There are many unique challenges that people with SCD face. For example, the transition from pediatric to adult care can be especially difficult, and many people struggle to find health care providers with comprehensive knowledge and expertise to provide proper care, especially in rural communities,” said ASH Vice President Alexis Thompson, MD, MPH, of the Ann and Robert H. Lurie Children’s Hospital of Chicago. “Given recent advances in research and treatment, there is enormous opportunity to transform the way we care for people suffering from SCD and conquer this disease.”
The Coalition will provide a platform to encourage stakeholders to work together to develop and implement important projects and activities that will ultimately help the SCD community and improve outcomes for individuals with the disease.
Examples of these important projects include:
- The American College of Emergency Physicians is supporting the Emergency Department Sickle Cell Care Coalition, a collaborative group that is dedicated to the improvement of the emergency care of individuals with sickle cell disease in the United States.
- The Food and Drug Administration recently launched a campaign to encourage minorities to participate in clinical trials for all medical conditions. The initial focus of the campaign is a series of videos to help the sickle cell disease community become “Clinical Trial Champions.”
- The Sickle Cell Disease Association of American continues to work with stakeholder groups as they further implement Get Connected, a patient powered registry program, as well as develop many new initiatives such as programs to expand the use of community health workers in sickle cell disease care and increase patient engagement in clinical trials.
- In the spring of 2016, the Centers for Disease Control and the Association of Public Health Laboratories released a guidance document on Hemoglobinopathy Laboratory Testing and Follow-up Techniques, which aims to strengthen newborn screening and diagnostic testing capabilities in the United States and around the globe by offering examples of best practices.
- The National Marrow Donor Program was recently instrumental to influencing the Centers for Medicare & Medicaid Services to modify the agency’s existing National Coverage Determinations Manual to expand national coverage for allogeneic hematopoietic stem cell transplantation for three hematologic conditions, including sickle cell disease.
For more information on the Coalition and its mission, visit http://www.scdcoalition.org.
# # #
About the American Society of Hematology (ASH)
The American Society of Hematology (ASH) (http://www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood(http://www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.
About the Sickle Cell Disease Coalition
The mission of the Sickle Cell Disease Coalition (SCDC) (http://www.scdcoalition.org) is to help amplify the voice of the SCD community, promote awareness, and improve outcomes for individuals with SCD. The Coalition is focused on promoting research, clinical care, education, training, and advocacy while providing a platform to encourage stakeholders to work together to develop and implement important projects and activities that will ultimately help the SCD community and improve outcomes for individuals with the disease. The Coalition is comprised of leading patient advocacy groups, people with SCD and their families, researchers, clinicians, policymakers, industry stakeholders, and foundations with an interest in SCD.